Company News & Events

ORYZON receives approval from MHRA to initiate Clinical Development of ORY-1001, a Novel LSD1 Inhibitor, in Patients with Acute Myeloid Leukemia in the United Kingdom

16 January 2014

The First Specific LSD1 Inhibitor to Enter the Clinic.

ORYZON, a biopharmaceutical company with a strong focus on epigenetics, has announced that has received the approval from the British Drug Agency (MHRA) on January 15th, 2014 to initiate a Phase I/IIA clinical trial of ORY-1001, a novel and highly selective LSD1 inhibitor, in patients with relapsed or refractory acute leukemia in the United Kingdom.

The company got the approval from the Spanish Drug Agency (AEMPS) a few weeks ago. This first-in-human trial is currently open at the Hospital Vall d’Hebron in Barcelona, Spain and additional study sites in Spain and in the United Kingdom will be incorporated shortly.

Click here to see the full Press Release.

Share this story